Introduction to Special Issue: Genomic Analysis of Common Disease
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(2), P. 112 - 112
Published: Feb. 10, 2025
The
development
of
NextGen
or
massive
parallel
sequencing
[...].
Language: Английский
Cell-free DNA: plays an essential role in early diagnosis and immunotherapy of pancreatic cancer
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 7, 2025
Pancreatic
cancer
is
renowned
for
its
aggressive
nature
and
dismal
prognosis,
with
the
majority
of
patients
diagnosed
at
an
advanced
stage.
The
prognosis
pancreatic
can
be
improved
by
early
diagnosis
effective
treatment.
Circulating
cell-free
DNA
(cfDNA)
has
emerged
as
a
promising
biomarker
monitoring
cancer.
This
research
presents
review
circulating
essential
role
in
immunotherapy
detection
methods
cfDNA,
potential
diagnostic
biomarker,
latest
progress
cfDNA-based
are
discussed.
findings
suggest
that
cfDNA
plays
vital
personalised
treatment
cancer,
holding
great
promise
improving
patient
outcomes.
Language: Английский
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications
Paola Barone,
No information about this author
Adele Bottaro,
No information about this author
Rossana Leanza
No information about this author
et al.
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(4), P. 227 - 227
Published: March 26, 2025
Myeloproliferative
neoplasms
are
clonal
hematological
characterized
by
excessive
proliferation
of
cells
erythroid,
granulocytic,
and
megakaryocytic
lineage.
The
genetic
mechanisms
underlying
this
group
blood
diseases
now
known,
but
new
perspectives
have
recently
emerged
in
the
field
epigenetics
particularly
related
to
possible
role
DNA
methylation
disease
development
progression.
regulates
different
cellular
processes,
such
as
proliferation,
differentiation,
apoptosis.
In
myeloproliferative
neoplasms,
a
link
has
been
found
between
abnormal
patterns,
hypermethylation
tumor
suppressors
or,
conversely,
oncogenes
hypomethylation,
with
progression
disease,
spreading
important
prognostic
therapeutic
implications.
This
review
aims
investigate
relationship
alterations
emphasizing
ways
which
epigenetic
dysregulation
promotes
biology.
Language: Английский
LINE-1 cfDNA Methylation as an Emerging Biomarker in Solid Cancers
Cancers,
Journal Year:
2024,
Volume and Issue:
16(22), P. 3725 - 3725
Published: Nov. 5, 2024
Epigenetic
dysregulation
is
a
hallmark
of
many
human
malignancies,
with
DNA
methylation
being
primary
mechanism
influencing
gene
expression
and
maintaining
genomic
stability.
Genome-wide
hypomethylation,
characteristic
cancers,
partly
attributed
to
the
demethylation
repetitive
elements,
including
LINE-1,
prevalent
non-LTR
retrotransposon.
The
status
LINE-1
closely
associated
overall
levels
in
tumors.
cfDNA
comprises
extracellular
fragments
found
bodily
fluids
such
as
plasma,
serum,
urine,
offering
dynamic
snapshot
genetic
epigenetic
landscape
This
real-time
sampling
provides
minimally
invasive
avenue
for
cancer
diagnostics,
prognostics,
monitoring.
has
emerged
promising
biomarker,
several
studies
highlighting
its
potential
diagnosing
predicting
outcomes
patients.
Recent
research
also
suggests
that
cfDNA-based
analysis
could
serve
valuable
tool
evaluating
efficacy
therapies,
immunotherapy.
growing
clinical
significance
calls
closer
examination
components,
particularly
elements
like
LINE-1.
Despite
their
importance,
role
not
been
thoroughly
gauged.
We
aim
address
this
gap
by
reviewing
current
literature
on
assays,
focusing
applications
diagnostics
disease
Language: Английский